Shots: The P-III ASCEND program includes 5 studies i.e ASCEND-ND, D, ID, NHQ & TD studies evaluating efficacy & safety of daprodustat vs ESA in ~8,000 patients with anemia due […]readmore
Tags : Five
Shots: Codiak to receive up to $72.5M upfront, near-term license payments along with research funding and is eligible to receive development and regulatory milestone payments and tiered royalties on future […]readmore
Shots: Lyell to apply its technologies to strengthen GSK’s cell therapy pipeline including GSK3377794 targeting the NY-ESO-1 antigen expressed along multiple cancer plus an approach to counter T cell exhaustion […]readmore
Biosimilars
Regulatory
Pfizer’s Zirabev (biosimilar, bevacizumab) Receives the US FDA’s Approval for
Shots: The approval is based on REFLECTIONS B7391003 study results assessing Zirabev vs reference product Avastin, in patients with advanced non-sq NSCLC The study resulted in biosimilarity data, showing clinical […]readmore
Shots: Aronora to receive $6M upfront & $3M upon fulfillment of certain conditions. Xoma to get rights to royalties and 10% of milestone payments associated with five hematology assets from […]readmore
Crown to get North American rights of GSK’s OTC drugs namely, PanOxyl, Sarna, Zeasorb, Desenex, Mineral Ice The focus of the acquisition is to build Crown’s footprints in North […]readmore